46
DOYLESTOWN, Pa. — August 28, 2025 — Leads & Copy — Aprea Therapeutics, Inc. (Nasdaq: APRE) will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. The presentation is scheduled for Tuesday, September 9, at 3:30 PM ET at the Lotte New York Palace Hotel. A webcast will be available for 90 days.
Aprea is focused on developing novel cancer therapies. Its lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both in clinical development for solid tumor indications.
Investor Contact: Mike Moyer, LifeSci Advisors, mmoyer@lifesciadvisors.com
Source: Aprea Therapeutics, Inc.
